2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin's and Non-Hodgkin Lymphomas.

Adapted; Assessment; DLBCL; Hodgkin; Lymphoma; PET; Therapy; Fluorodeoxyglucose F18; Radiopharmaceuticals; Humans; Neoplasm Staging; Positron-Emission Tomography/methods; Hodgkin Disease/diagnostic imaging; Positron Emission Tomography Computed Tomography/methods; Lymphoma, Non-Hodgkin/diagnostic imaging; Hodgkin Disease; Lymphoma, Non-Hodgkin; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiation; Radiology, Nuclear Medicine and Imaging

Abstract :

[en] The 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography combined with computed tomography (PET/CT) has contributed to outcome improvement of patients with lymphoma. The use of [18F]FDG PET/CT for staging and response assessment is successfully applied both in routine clinical practice and in clinical trials. The challenges lie in enhancing the outcomes of lymphoma patients, particularly those with advanced or refractory/relapsed disease, and to minimize the long-term toxicity associated with treatments, including radiation therapy. The objective of this review article is to present contemporary data on the use of [18F]FDG PET/CT for treatment assessment of aggressive lymphomas.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Withofs, Nadia ; Université de Liège - ULiège > Département des sciences cliniques

Bonnet, Christophe ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Language :

English

Title :

2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin's and Non-Hodgkin Lymphomas.

Publication date :

October 2024

Journal title :

PET Clinics

ISSN :

1556-8598

eISSN :

1879-9809

Publisher :

W.B. Saunders, United States

Volume :

Issue :

Pages :

447 - 462

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S1556859824000476?httpAccept=text/xml

Available on ORBi :

since 24 September 2024

Statistics

Number of views

40 (0 by ULiège)

Number of downloads

13 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. Cancer statistics, 2022. CA Cancer J Clin 72:1 (2022), 7–33.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas. Version 1.2024 — January 18, 2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Alaggio, R., Amador, C., Anagnostopoulos, I., et al. The 5th edition of the World Health Organization classification of Haematolymphoid tumours: Lymphoid neoplasms. Leukemia 36:7 (2022), 1720–1748.
Cheson, B.D., Fisher, R.I., Barrington, S.F., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:27 (2014), 3059–3068.
Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international Conference on malignant lymphomas imaging working group. J Clin Oncol 32:27 (2014), 3048–3058.
Cheson, B.D., Ansell, S., Schwartz, L., et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:21 (2016), 2489–2496.
Ricard, F., Cheson, B., Barrington, S., et al. Application of the Lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the PRoLoG consensus initiative (Part 1-clinical). J Nucl Med 64:1 (2023), 102–108.
Ricard, F., Barrington, S., Korn, R., et al. Application of the Lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the PRoLoG consensus initiative (Part 2-Technical). J Nucl Med 64:2 (2023), 239–243.
Nanni, C., Kobe, C., Baessler, B., et al. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol 10:5 (2023), e367–e381.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma. Version 1.2024-October 12, 2023 © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Hasenclever, D., Diehl, V., A prognostic score for advanced Hodgkin's disease. International prognostic factors Project on advanced Hodgkin's disease. N Engl J Med 339:21 (1998), 1506–1514.
Borchmann, P., Plutschow, A., Kobe, C., et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:2 (2021), 223–234.
Fuchs, M., Goergen, H., Kobe, C., et al. Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol 37:31 (2019), 2835–2845.
Fuchs, M., Jacob, A.S., Kaul, H., et al. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia 38:1 (2024), 160–167.
Fornecker, L.M., Lazarovici, J., Aurer, I., et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol 41:2 (2023), 327–335.
Straus, D.J., Jung, S.H., Pitcher, B., et al. Calgb 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:10 (2018), 1013–1021.
Andre, M.P.E., Girinsky, T., Federico, M., et al. Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:16 (2017), 1786–1794.
Federico, M., Fortpied, C., Stepanishyna, Y., et al. Long-term follow-up of the response-adapted Intergroup EORTC/LYSA/FIL H10 trial for Localized hodgkin lymphoma. J Clin Oncol 42:1 (2024), 19–25.
Radford, J., Illidge, T., Counsell, N., et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 372:17 (2015), 1598–1607.
Johnson, P., Federico, M., Kirkwood, A., et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 374:25 (2016), 2419–2429.
Barrington, S.F., Kirkwood, A.A., Franceschetto, A., et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 127:12 (2016), 1531–1538.
Luminari, S., Fossa, A., Trotman, J., et al. Long-term follow-up of the response-adjusted therapy for advanced hodgkin lymphoma trial. J Clin Oncol, 42(1), 2024 13-18.
Eichenauer, D.A., Aleman, B.M.P., Andre, M., et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:Suppl 4 (2018), iv19–iv29.
Fiaccadori, V., Neven, A., Fortpied, C., et al. Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials. Br J Haematol 200:6 (2023), 731–739.
Sickinger, M.T., von Tresckow, B., Kobe, C., et al. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis. Crit Rev Oncol Hematol 101 (2016), 86–92.
Follows, G.A., Barrington, S.F., Bhuller, K.S., et al. Guideline for the first-line management of classical hodgkin lymphoma - a British Society for Haematology guideline. Br J Haematol 197:5 (2022), 558–572.
Gillessen, S., Plutschow, A., Fuchs, M., et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 8:4 (2021), e278–e288.
von Tresckow, B., Plutschow, A., Fuchs, M., et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:9 (2012), 907–913.
Stephens, D.M., Li, H., Schoder, H., et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 134:15 (2019), 1238–1246.
Press, O.W., Li, H., Schoder, H., et al. US Intergroup trial of response-adapted therapy for stage III to IV hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816. J Clin Oncol 34:17 (2016), 2020–2027.
Casasnovas, R.O., Bouabdallah, R., Brice, P., et al. Positron emission tomography-driven strategy in advanced hodgkin lymphoma: Prolonged follow-up of the AHL2011 phase III lymphoma study association study. J Clin Oncol 40:10 (2022), 1091–1101.
Casasnovas, R.O., Bouabdallah, R., Brice, P., et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:2 (2019), 202–215.
Borchmann, P., Goergen, H., Kobe, C., et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:10114 (2017), 2790–2802.
Andre, M.P.E., Carde, P., Viviani, S., et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 9:18 (2020), 6565–6575.
Ansell, S.M., Radford, J., Connors, J.M., et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med 387:4 (2022), 310–320.
Hutchings, M., Radford, J., Ansell, S.M., et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol 39:2 (2021), 185–195.
Connors, J.M., Jurczak, W., Straus, D.J., et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 378:4 (2018), 331–344.
Herrera, A.F., LeBlanc, M.L., Castellino, S.M., et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol, 41(17_suppl), 2023, LBA4.
Lynch, R.C., Ujjani, C.S., Poh, C., et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood 141:21 (2023), 2576–2586.
Mauz-Korholz, C., Landman-Parker, J., Balwierz, W., et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 23:1 (2022), 125–137.
Ferdinandus, J., van Heek, L., Roth, K., et al. Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group. Eur J Nucl Med Mol Imaging 51:2 (2024), 490–495.
Sehn, L.H., Berry, B., Chhanabhai, M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:5 (2007), 1857–1861.
Fox, C.P., Chaganti, S., McIlroy, G., et al. The management of newly diagnosed large B-cell lymphoma: a British Society for Haematology Guideline. Br J Haematol, 2024, 10.1111/bjh.19273.
Burggraaff, C.N., de Jong, A., Hoekstra, O.S., et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 46:1 (2019), 65–79.
Eertink, J.J., Burggraaff, C.N., Heymans, M.W., et al. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv 5:9 (2021), 2375–2384.
Kostakoglu, L., Martelli, M., Sehn, L.H., et al. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv 5:5 (2021), 1283–1290.
Lamy, T., Damaj, G., Soubeyran, P., et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131:2 (2018), 174–181.
Poeschel, V., Held, G., Ziepert, M., et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 394:10216 (2019), 2271–2281.
Bologna, S., Vander Borght, T., Briere, J., et al. Early positron emission tomography response-adapted treatment in Localized diffuse large B-cell lymphoma (Aaipi=0) : results of the phase 3 Lysa Lnh 09-1b trial. Hematol Oncol, 39(S2), 2021.
Persky, D.O., Li, H., Stephens, D.M., et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National clinical trials Network study S1001. J Clin Oncol 38:26 (2020), 3003–3011.
Pfreundschuh, M., Murawski, N., Christofyllakis, K., et al. Excellent outcome of elderly patients with favourable-prognosis DLBCL treated with 4 cycles CHOP/Chlip-14 plus 8 applications of rituximab and a PET-based intensification strategy that includes involved-site radiotherapy (IS-RT): results of the first 120 patients of the OPTIMAL>60 trial of the Dshnhl. Blood, 130(Supplement 1), 2017, 1549.
Burggraaff, C.N., Eertink, J.J., Lugtenburg, P.J., et al. 18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: the HOVON-84 study. J Nucl Med 63:7 (2022), 1001–1007.
Michaud, L., Bantilan, K., Mauguen, A., et al. Prognostic value of 18F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted Immunochemotherapy regimen. J Nucl Med 64:4 (2023), 536–541.
Cottereau, A.S., Meignan, M., Nioche, C., et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(dagger). Ann Oncol 32:3 (2021), 404–411.
Barrington, S.F., Meignan, M., Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med 60:8 (2019), 1096–1102.
Barrington, S.F., Cottereau, A.S., Zijlstra, J.M., Is 18F-FDG metabolic tumor volume in lymphoma really happening?. J Nucl Med 65:4 (2024), 510–511.
Mikhaeel, N.G., Heymans, M.W., Eertink, J.J., et al. Proposed new Dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol 40:21 (2022), 2352–2360.
Eertink, J.J., Zwezerijnen, G.J.C., Heymans, M.W., et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood 141:25 (2023), 3055–3064.
Barrington, S.F., Zwezerijnen, B., de Vet, H.C.W., et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med 62:3 (2021), 332–337.
Hutchings, M., The evolving therapy of DLBCL: bispecific antibodies. Hematol Oncol 41:S1 (2023), 107–111.
Rekowski, J., Huttmann, A., Schmitz, C., et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the DeltaSUV(max) method. J Nucl Med 62:1 (2021), 37–42.
Duarte, S., Roque, A., Saraiva, T., et al. Interim FDG18-PET SUV(max) variation adds prognostic value to Deauville 5-point scale in the identification of patients with ultra-high-risk diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk 23:2 (2023), e107–e116.
Allioux, F., Gandhi, D., Vilque, J.P., et al. End-of-treatment 18F-FDG PET/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score. Leuk Lymphoma 62:12 (2021), 2890–2898.
Itti, E., Blanc-Durand, P., Berriolo-Riedinger, A., et al. Validation of the DeltaSUV(max) for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical trial. J Nucl Med 64:11 (2023), 1706–1711.
Eertink, J.J., Arens, A.I.J., Huijbregts, J.E., et al. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. Eur J Nucl Med Mol Imaging 49:3 (2022), 943–952.
Kuhnl, A., Roddie, C., Kirkwood, A.A., et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv 6:1 (2022), 321–326.
Danylesko, I., Shouval, R., Shem-Tov, N., et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant 56:5 (2021), 1134–1143.
Cohen, D., Luttwak, E., Beyar-Katz, O., et al. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging 49:3 (2022), 953–962.
Adams, H.J.A., Kwee, T.C., Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol 85:11 (2016), 1963–1970.
Sasse, S., Brockelmann, P.J., Goergen, H., et al. Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: Updated analyses of the German hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35:18 (2017), 1999–2007.
Oeffinger, K.C., Stratton, K.L., Hudson, M.M., et al. Impact of risk-adapted therapy for pediatric hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study. J Clin Oncol 39:20 (2021), 2266–2275.
Lo, A.C., Liu, A., Liu, Q., et al. Late cardiac toxic effects associated with treatment protocols for hodgkin lymphoma in children. JAMA Netw Open, 7(1), 2024, e2351062.
Giulino-Roth, L., Pei, Q., Buxton, A., et al. Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 137:11 (2021), 1449–1456.
Wirth, A., Mikhaeel, N.G., Aleman, B.M.P., et al. Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys 107:5 (2020), 909–933.
Sieniawski, M., Reineke, T., Nogova, L., et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 111:1 (2008), 71–76.
Merli, F., Luminari, S., Gobbi, P.G., et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 34:11 (2016), 1175–1181.
Demeestere, I., Racape, J., Dechene, J., et al. Gonadal function recovery in patients with advanced hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011). J Clin Oncol 39:29 (2021), 3251–3260.
van Heek, L., Stuka, C., Kaul, H., et al. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - data from the prospective, multicenter phase III HD16 trial. BMC Cancer, 22(1), 2022, 672.
Alig, S.K., Shahrokh Esfahani, M., Garofalo, A., et al. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature 625:7996 (2024), 778–787.
Ghesquieres, H., Cherblanc, F., Belot, A., et al. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort. Blood Adv 8:2 (2024), 296–308.
Veziroglu, E.M., Farhadi, F., Hasani, N., et al. Role of artificial intelligence in PET/CT imaging for management of lymphoma. Semin Nucl Med 53:3 (2023), 426–448.
Hasani, N., Paravastu, S.S., Farhadi, F., et al. Artificial intelligence in lymphoma PET imaging: a scoping review (current trends and future directions). Pet Clin 17:1 (2022), 145–174.